Indication
Chronic Myeloid
3 clinical trials
4 products
3 drugs
Clinical trial
A Phase 2, Multi-center, Open-label, Randomized Study of Oral Asciminib Added to Imatinib Versus Continued Imatinib Versus Switch to Nilotinib in Patients With CML-CP Who Have Been Previously Treated With Imatinib and Have Not Achieved Deep Molecular ResponseStatus: Active (not recruiting), Estimated PCD: 2021-11-08
Product
AsciminibProduct
ImatinibProduct
NilotinibClinical trial
Pilot Study of Imatinib Discontinuation in Patients With Chronic Myeloid Leukemia With Deep Molecular Response - Evaluation of Pioglitazone in Treatment-free Remission (EDI-PIO)Status: Active (not recruiting), Estimated PCD: 2024-02-01
Product
PioglitazoneClinical trial
Phase-III Randomized Study to Optimize TKIs Multiple Approaches - (OPTkIMA) - and Quality of Life (QoL) in Elderly Patients (≥60 Years) With Ph+ Chronic Myeloid Leukemia (CML) and MR3.0 / MR4.0 Stable Molecular ResponseStatus: Recruiting, Estimated PCD: 2023-12-31
Drug
imatinibDrug
nilotinibDrug
dasatinib